Tyme Technologies, Inc. (TYME): Price and Financial Metrics

Tyme Technologies, Inc. (TYME): $0.31

0.02 (+8.07%)

POWR Rating

Component Grades








Add TYME to Watchlist
Sign Up

TYME Price/Volume Stats

Current price $0.31 52-week high $1.14
Prev. close $0.29 52-week low $0.22
Day low $0.29 Volume 2,678,100
Day high $0.32 Avg. volume 1,009,732
50-day MA $0.30 Dividend yield N/A
200-day MA $0.37 Market Cap 53.50M

TYME Stock Price Chart Interactive Chart >

Tyme Technologies, Inc. (TYME) Company Bio

Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company was founded in 2011 and is based in New York, New York.

TYME Latest News Stream

Event/Time News Detail
Loading, please wait...

TYME Latest Social Stream

Loading social stream, please wait...

View Full TYME Social Stream

Latest TYME News From Around the Web

Below are the latest news stories about TYME TECHNOLOGIES INC that investors may wish to consider to help them evaluate TYME as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting off the final trading day of the week with a look at the biggest pre-market stock movers for Friday and what's moving them!

William White on InvestorPlace | September 16, 2022

Syros and Tyme Technologies Announce Stockholder Approval of Merger

-- Combined Company to Trade on Nasdaq Under Ticker “SYRS” ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 20

Yahoo | September 15, 2022

TYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and Tyme

BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”), today announced that independent proxy advisory firms Glass, Lewis & Co. (“Glass Lewis”) and Institutional Shareholder Services Inc. (“ISS”) have recommended that Tyme stockholders vote “FOR” the previously announced merger of Tyme and Syros Pharmaceuticals, Inc. (“Syros”) and “FOR” all other matters to be voted upon at the Company’s upcoming Special Meeting of Stockholders (the

Yahoo | September 7, 2022

Mass. M&A activity picks up among life sciences firms

Mergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are still yet to come.

Yahoo | July 28, 2022

Syros to acquire New Jersey biotech Tyme Technologies

Syros Pharmaceuticals is set to acquire a New Jersey biotech firm called Tyme Technologies Inc., extending its cash runway into 2025 at a time when biotech stocks are being hammered.

Yahoo | July 5, 2022

Read More 'TYME' Stories Here

TYME Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -79.47%
5-year -79.05%
2023 N/A
2022 0.00%
2021 -50.57%
2020 -12.86%
2019 -62.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!